Gilead Sciences’ Vosevi (sofosbuvir/velpatasvir/voxilaprevir) boasted a high hepatitis C virus (HCV) cure rate among individuals who had been treated for the virus before in a recent study, Reuters Health reports.

Publishing their findings in The Lancet, researchers conducted a sub-study of the Phase III POLARIS-1 trial. The sub-study included 147 participants who received a placebo during the placebo phase of the larger study. All of them had previously been treated for hep C with a direct-acting antiviral in the NS5A inhibitor class.

After 12 weeks of Vosevi treatment, 143 (97 percent) of the participants achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure). The cure rate was 97 percent (127 of 131) among those who initially had HCV with mutations associated with drug resistance and 100 percent among the 16 participants who did not have such resistance mutations or whose resistance mutation status could not be determined.

The most common adverse health events included fatigue, headache, diarrhea and nausea. No participants experienced serious adverse health events that the study authors determined were related to Vosevi. No one stopped treatment because of adverse health events.

To read the Reuters Health article, click here.

To read the study abstract, click here.